Fit for high altitude: are hypoxic challenge tests useful?
© Novamedia srl 2011
Received: 13 December 2010
Accepted: 12 January 2011
Published: 28 February 2011
Altitude travel results in acute variations of barometric pressure, which induce different degrees of hypoxia, changing the gas contents in body tissues and cavities. Non ventilated air containing cavities may induce barotraumas of the lung (pneumothorax), sinuses and middle ear, with pain, vertigo and hearing loss. Commercial air planes keep their cabin pressure at an equivalent altitude of about 2,500 m. This leads to an increased respiratory drive which may also result in symptoms of emotional hyperventilation. In patients with preexisting respiratory pathology due to lung, cardiovascular, pleural, thoracic neuromuscular or obesity-related diseases (i.e. obstructive sleep apnea) an additional hypoxic stress may induce respiratory pump and/or heart failure. Clinical pre-altitude assessment must be disease-specific and it includes spirometry, pulsoximetry, ECG, pulmonary and systemic hypertension assessment. In patients with abnormal values we need, in addition, measurements of hemoglobin, pH, base excess, PaO2, and PaCO2 to evaluate whether O2- and CO2-transport is sufficient.
Instead of the hypoxia altitude simulation test (HAST), which is not without danger for patients with respiratory insufficiency, we prefer primarily a hyperoxic challenge. The supplementation of normobaric O2 gives us information on the acute reversibility of the arterial hypoxemia and the reduction of ventilation and pulmonary hypertension, as well as about the efficiency of the additional O2-flow needed during altitude exposure. For difficult judgements the performance of the test in a hypobaric chamber with and without supplemental O2-breathing remains the gold standard. The increasing numbers of drugs to treat acute pulmonary hypertension due to altitude exposure (acetazolamide, dexamethasone, nifedipine, sildenafil) or to other etiologies (anticoagulants, prostanoids, phosphodiesterase-5-inhibitors, endothelin receptor antagonists) including mechanical aids to reduce periodical or insufficient ventilation during altitude exposure (added dead space, continuous or bilevel positive airway pressure, non-invasive ventilation) call for further randomized controlled trials of combined applications.
Idoneità all’alta montagna: i test all’ipossia sono davvero utili?
Portarsi in alta quota implica variazioni in acuto della pressione barometrica che comportano vari gradi di ipossia, modificazioni nel contenuto di gas nei tessuti corporei e nelle cavità. L’aria non ventilata contenuta nelle cavità può indurre barotraumi del polmone (pneumotorace), dei seni paranasali e dell’orecchio medio, con possibile dolore, vertigine e perdita dell’udito. Gli aerei commerciali pressurizzano le loro cabinead un equivalente di circa 2.500 m di altitudine. Questo comporta un aumento del drive respiratorio che può giungere a dare gli stessi sintomi dell’iperventilazione su base emotiva. Nei pazienti con patologie respiratorie preesistenti, con malattie polmonari, cardiovascolari, pleuriche, neuromuscolari toraciche o correlate all’obesità (es.: apnee ostruttive nel sonno) lo stress ipossico supplementare può portare all’insufficienza respiratoria o cardiaca.
La valutazione clinica prima dell’esposizione alla quota deve perciò essere specifica per la patologia ed includere spirometria, pulsossimetria, ECG, valutazione della pressione arteriosa sistemica e polmonare. Nei pazienti con valori anormali si rendono necessarie ulteriori valutazioni di emoglobina, pH, eccesso di basi, PaO2, e PaCO2 per valutare se il trasporto di O2 e di CO2 sia sufficiente.
Piuttosto che il test di simulazione dell’ipossia da alta quota (HAST), che non è privo di pericoli per i pazienti in insufficienza respiratoria, preferiamo in prima battuta un test iperossico. Infatti il supplemento di O2 in normobaria ci fornisce le informazioni sulla reversibilità acuta dell’ipossiemia arteriosa e sulla riduzione di ventilazione e pressione arteriosa polmonare, così come sull’efficienza del supplemento di O2 necessario durante l’esposizione in alta quota. In caso di risultato inconclusivo la ripetizione del test con e senza O2 in camera ipobarica rimane il gold standard.
Il crescente numero di farmaci per il trattamento dell’ipertensione polmonare acuta da alta quota (acetazolamide, desametasone, nifedipina, sildenafil) e da altre eziologie (anticoagulanti, prostanoidi, inibitori della fosfodiesterasi-5, antagonisti dei recettori per l’endotelina), compresi i supporti meccanici per ridurre la ventilazione a carattere periodico o insufficiente durante l’esposizione all’alta quota (spazio morto, pressione positiva continua o bilevel, ventilazione non invasiva) richiedono decisamente un maggior numero di studi controllati e randomizzati sulle loro azioni combinate.
Altitude exposure became an increasingly common phenomenon during the 20th century due to the popularity of various sporting activities (skiing, mountaineering, trekking) and greater availability of transport facilities (air planes, cars, trains, cable cars).
Acute altitude-related illnesses
Acute altitude exposure
A sudden cabin pressure loss of commercial air planes at altitudes above 5,000-6,000 m or a rapid ascent to this altitude breathing air under ambient pressure can lead to decompression illness similar to that recognised in diving accidents. Acute hypoxic exposure (balloon rides) may induce signs of emotional hyperventilation, problems to speak, to calculate followed by dizziness, nausea and vomiting, but also uncritical euphoria. This situation can be simulated in hypobaric chambers to demonstrate the danger of altitude hypoxia to pilots and to study patients at risk with or without O2 breathing [2–5].
Acute mountain sickness (AMS)
AMS affects 10-40% of lowlanders ascending to moderate altitudes above 2,500 m and 60% of subjects who reach altitudes of 4,000-5,000 m within a few hours. Physical fitness does not protect against any high altitude related illnesses. The incidence of AMS depends on ascent rate, whether the journey is made by climbing or travelling by plane (La Paz, Bolivia airport is at 4,100 m), car or train (the Chinese Tibet railway reaches 5,000 m).
Lake louise acute mountain sickness scoring system
Self reported symptoms: (Score)
no (0), mild (1), moderate (2), severe, incapacitating (3)
no (0), poor appetite or nausea (1), moderate nausea or nausea (2), severe nausea and vomiting, incapacitating (3)
Fatigue and/or weakness:
no (0), mild (1), moderate (2), severe (3)
Dizziness or light headedness:
no (0), mild (1), moderate (2), severe, incapacitating (3)
Difficulty to sleep:
as well as usual (0), not as well as usual (1), poor night sleep, woke up many times (2), could not sleep at all (3)
Clinical assessment: (Score)
Change in mental status:
no (0), lethargy or lassitude (1), disorientated or confused (2), stupor or semi-consciousness (3), coma (4)
Ataxia (heel-to-toe walking):
no (0), manoeuvres to maintain balance (1), steps off line (2), falls down (3), cannot stand (4)
no (0), at one location (1), at two or more locations (2),
If you have any symptoms
how do they affect your activity?:
no reduction (0), mild (1), moderate (2), severe reduction, e.g bed rest (3)
High altitude pulmonary edema (HAPE)
HAPE develops at altitudes above 2,500 m. It is a high-permeability pulmonary edema caused by elevated pulmonary capillary pressures due to alveolar hypoxia . It may affect primarily only one lung. The initial onset is usually at night and not related to the frequently observed periodic breathing at altitude, which is a major cause of poor sleep quality. This so-called Cheyne-Stokes breathing is common in normal subjects at altitude and disappears, like AMS, during the first three nights. Chronic periodic breathing has also been observed above 4,500 m lasting for weeks.
Recent studies showed that HAPE is more frequent in subjects with patent foramen ovale (PFO) who develop at altitude an increasing right to left shunt due to the hypoxic pulmonary vasoconstriction. In general the mean O2-saturation at normal barometric pressures is lower in subjects who developed HAPE at altitude compared to HAPE-resistant climbers. It is not clear whether closure of PFO prevents HAPE in these patients.
The symptoms of HAPE are dry cough, decreased exercise performance, dyspnea at rest, orthopnea, cyanosis, tachypnea (> 25 breaths/min), tachycardia (> 100 beats/min), low grade fever, crackles on pulmonary auscultation and ultimately hemoptysis and death.
Prevention of altitude related illness
A slow and gradual ascent with sufficient time and a recreational sleep before ascent is the best strategy for successful acclimatisation. Also the sleeping altitude prior to higher exposures and the individual susceptibility is important. To prevent altitude-related sickness, not more than a 500 m increase of sleeping altitude per day above 2,500 m is recommended, albeit there is little evidence to support this. For a safe ascent, the general recommendation is: climb high, sleep low, avoid doing more physical exercise than needed. If this is not possible for logistic or other reasons a prophylactic pharmacological treatment to prevent symptoms of AMS, periodic breathing and non-recreational sleep is recommended: acetazolamide (Diamox®) 125 mg the evening before ascent above 2,500 m and later twice daily for a stay of some days. Possible side effects are gastrointes tinal symptoms and paresthesias. Dexamethasone 4 mg can be taken the evening before ascent and later twice daily, especially in patients with a history of asthma and for prevention of HACE and HAPE. In subjects with a history of HAPE, 30-40 mg of slow release nifedipine may be given in addition. Mountaineers with severe sleep disordered breathing at altitude improve their nocturnal sleep quality by using benzodiazepines and/or a fitted mask with a dead space of 500 ml .
Management of manifest high altitude diseases
Mild and moderate AMS
Rest, avoidance of exertion, acclimatisation, analgesia, antiemetics, and azetazolamide 250 mg twice daily until descent are recommended. Treatment of periodic breathing and sleep disturbances is also primarily with acetazolamide which stabilizes nocturnal O2-saturation, reduces awakenings and hence improves sleep quality. In addition benzodiazepines taken before sleeping (Tenazepam® 10 mg) result in a significant decrease of periodic breathing without reduction of next-day reaction time, wakefulness, cognition and AMS-symptoms. Immediate descent is generally not indicated in mild forms of AMS.
Severe AMS and HACE
Immediate descent below 2,500 m is recommended. If available, O2 with or without pressure bag should be administered. Drug therapy consists of acetazolamide 125 mg twice daily, or dexamethasone 8 mg and later 4 mg every 6 hours.
HAPE and/or HACE
O2 breathing in- or outside a pressure bag, and 10-20 mg slow release nifedipine and 8 mg dexamethsone every 6 hours are recommended . Against headaches and pulmonary hypertension, sildenafil should be administered (Revatio®, Viagra®) as a vasodilator . Immediate descent below 2,500 m is recommended whenever possible. In all cases, dehydration is a risk and it is important to ensure a careful control of fluid balance.
Subacute and chronic mountain sickness (cms)
Some persons do not acclimatize to altitudes of 2,500-5,000 m. In these patients AMS-symptoms and sleep disturbances due to periodic breathing persist. Other subjects apparently well adapted to these altitudes for many months or years develop CMS, also called Monge's disease, characterized by excessive production of red cells (with the risk of thromboembolic complications), hypoventilation, fatigue, dyspnea, cyanosis, clubbing of the fingers and leg edema with cor pulmonale. If the patient descends to lower altitudes, preferably at sea level, these symptoms disappear within months without need for further treatment. It seems that increasing the respiratory dead space by a fitted mask improves disordered breathing and might improve erythrocytosis and pulmonary hypertension also in CMS . The Pickwickian-like syndrome is characterized by a primary depression of breathing without upper airway obstruction, such as in patients with obstructive sleep apnea syndrome (OSAS). The diagnosis requires exclusion of other causes of chronic respiratory insufficiency such as chronic obstructive pulmonary disease (COPD), obesity related hypoventilation or primary heart diseases causing polycythemia. CMS was first described in 1928 in mine workers living in the Andes of south America at an altitude between 3,000 and 5,000 m. Chronic altitude exposure during pregnancy leads to a reduced birth-weight of the child. Deliveries at altitudes above 2,500 m for non-residents (also in aircraft) have an increased risk of neonatal death compared to non-hypoxic environments (early closure of ductus botalli and hypoxic vasoconstriction of the placenta vessels). Children exposed to high altitude have less periodic breathing at night than adults.
Altitude exposure with pre-existing respiratory diseases
Diseases of the lung and/or respiratory pump affect the O2 and CO2 transport which is further impaired by altitude exposure. Prophylactic recommendations and measures require disease-specific evaluation of these patients prior to high altitude travel.
The British Thoracic Society (BTS) recommendations give detailed advice for doctors dealing with patients suffering from respiratory disorders who are planning air travel. Two billion passengers currently fly worldwide each year on commercial planes, about 5% having problems [13, 14].
Flying with no or partial compensation of the environmental barometric pressures at cruising altitudes should be known in advance as well as the intended and final altitude of the travel (landing place).
Previous episodes of complications (the need for supplemental oxygen, pulmonary hypertension, asthma attacks, emotional hyperventilation, thrombo-embolic and cardiac diseases), decompression and recompression symptoms during altitude travel (difficulties in ventilating the middle ear and the sinuses), previous pneumothorax, obstructive and restrictive ventilatory defects and other causes of respiratory impairment should be carefully evaluated (lung function tests and pulse oximetry) during the medical consultation.
Pneumothorax and other forms of "trapped air"
Exposure of patients to moderate altitude, (such as in Davos, Switzerland or Denver, US) breathing dry air without strenuous exercise tends to improve asthmatic symptoms, probably because of the lower allergen load. This is especially the case for house dust mite sensitive subjects, because the house dust mite cannot reproduce at altitude levels with low humidity. Acute exposure to higher altitudes or breathing cold air during exercise may trigger hyperventilation-induced or so-called exercise-induced asthma. Longer stays at altitudes of more than 4,000 m generally reduce the bronchial hyper-responsiveness of mildly asthmatic patients .
Asthmatic subjects should maintain their pre-existing 'controller' medication and be equipped with an adequate supply of 'rescue' medications in the form of inhaled bronchodilators and oral steroids with appropriate instructions on their use. Breathing cold dry air through a face mask may help to humidify and warm the air entering the upper airways to BTPS-conditions and hence reduce broncho-constriction and airway inflammation.
It is not uncommon in non-asthmatic subjects, as a result of the increasing hypoxic drive, to develop clinical signs of an emotional hyperventilation syndrome without bronchial obstruction and/or a vocal cord dysfunction syndrome. It is possible to differentiate these "asthma" patients often clinically with the help of a stethoscope.
Pulmonary hypertension due to other lung diseases
HAPE is a consequence of hypoxic pulmonary vasoconstriction (HPV) and may be associated with other diseases that cause a significant reduction of the pulmonary vascular bed . These include interstitial and vascular lung diseases (primary forms of pulmonary hypertension and thromboembolic pulmonary diseases). Patients with lung diseases associated with pre-existing pulmonary hypertension (mean PAP > 25 mm Hg at rest) are advised against high altitude travel. If travel at altitudes above 2,500 m is unavoidable, supplemental oxygen should be administered in all patients who have pulmonary hypertension at sea level. The non-hypoxic component of pulmonary hypertension should be treated according to the therapy necessary for the specific lung disease under normobaric conditions. If the patient has no pre-existing pharmacotherapy for pulmonary hypertension they should be given as prophylaxis slow release nifedipine (20 mg b.i.d.) for the duration of the stay at altitude. Alternatives, depending on the underlying lung disease, include sildenafil, tadalafil and dexamethasone to reduce the hypoxic increase of pulmonary hypertension due to altitude exposure. The acute therapeutic response of phosphodiesterase-5 inhibitors, cortico steroids, calcium channel blockers and other pulmonary vasodilators (bosentan, iloprost) makes it impossible to predict the long-term effect of these drugs on pulmonary artery pressure either at sea level or at altitude (16).
Since non-invasive pulmonary artery pressure measurements with ECHO are not easy to perform in COPD patients, spirometry is recommended. Patients with FEV1 < 1,5 L should be assessed with pulsoximetry and an arterial CO2 measurement. These allow to detect hypoxemia and hypercapnia today also non-invasively. If supplemental O2-breathing (2-4 L/min) does not lead to a sufficient O2 saturation of 94% (equivalent to 70-75 mm Hg PaO2) at the altitude level of assessment, the patient should not be recommended for hypoxic exposures above 2,500 m.
The same evaluation criteria can be applied to patients with cystic fibrosis .
Patients with hypercapnic ventilatory failure (global respiratory insufficiency) at sea level are generally not able to sustain the increased hypoxic drive at altitude without additional oxygen breathing. Often they need also ventilatory support (non invasive ventilation). An optimal antiobstructive inhalation therapy with tiotropium bromide, indacaterol, topical steroids and possibly oral theophylline, which has also a positive effect on AMS, should be established .
Interstitial lung diseases (ILD)
Pulmonary thromboembolic disease
Patients with known thromboembolic complications, including smoking females with underlying coagulopathy and/or oral contraceptive use, are at increased risk during long distance flights or bus travel or other activities with a high degree of immobility. Restricted leg movement, venous occlusion (backpacking) and dehydration should be avoided. Any anticoagulant therapy started at sea level should be continued at altitude together with all other drugs prescribed to reduce pulmonary hypertension and disease-specific symptoms. There are anecdotal reports that lung emboli after thoracic surgery are less frequent if the operation is performed above 1,800 m compared to in lowland hospitals.
Respiratory pump disorders
Few studies have examined patients with respiratory pump disorders. Patients needing non-invasive ventilation (NIV) as a consequence of pump failure, alone or in combination with lung diseases and respiratory muscle fatigue, are generally not fit for travelling to altitudes above 2,500 m. They should also avoid long distance flights without supplemental O2-breathing and the support of a mechanical ventilator.
Patients with this syndrome are at risk of cor pulmonale and hence acute right heart failure under an additional hypoxic stress at altitude inducing more pulmonary vasoconstriction. Nocturnal hypoxemia (especially during REM sleep) due to obesity induced hypoventilation predisposes to both AMS and HAPE. Pulmonary artery pressures at altitude increase in proportion to the body mass index (BMI > 30 kg/m2, PaCO2 during the day > 45 mm Hg). Patients without daytime pulmonary hypertension who need only continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) at night can travel to moderate altitudes with their devices, but should also get prophylactic drug therapy as needed.
Obstructive and/or central sleep apnea
Patients with OSAS develop already subclinical HAPE at moderate altitudes of 2,500-3,000 m . Their symptoms of AMS benefit from 750 mg/d acetazolamide as well as fluid retention and systemic blood pressure elevation. Pulmonary gas exchange improved during the verum compared to the placebo night . Patients with pulmonary hypertension and/or day time hypoxemia at sea level need slow release nifedipine 20 mg b.i.d. with supplemental oxygen at night.
Carotid surgery and control of breathing
The hypoxemic ventilatory response is reduced in patients who have undergone endarterectomy with damage to the carotid body. These patients may show no increase of ventilation under hypoxic stress and therefore they have a high risk of developing AMS and HACE. If these patients need to travel at altitude, they should be first tested for their hyperoxic ventilatory response, to verify if there is a supplemental O2-induced hypoventilation.
Neuromuscular diseases and thoracic malformations
Patients with muscular dystrophies, diaphragmatic paralysis, amyotrophic lateral sclerosis (ALS), Guillain-Barré syndrome or severe kyphoscolioses have limited ability to increase their ventilation as required for altitude adaptation. Often they first hypoventilate during sleep at night and later during day time at sea level and need non-invasive ventilation (NIV) or bi-level positive airway pressure (BiPAP). Any prior treatment with BiPAP or NIV should be continued at altitude. Nocturnal or even 24 hour supplemental O2-breathing may be indicated to avoid at altitude an additional alveolar hypoxia-induced pulmonary vasoconstriction. Patients with kyphoscoliosis and pulmonary hypertension need additional oxygen combined with slow release nifedipine 20 mg b.i.d. In patients with bilateral diaphragmatic paralysis NIV is already indicated during moderate altitude exposure.
In conclusion, what do we need to evaluate if a patient is fit for altitude exposure? In the first instance, the patient's clinical diagnosis, medical examination and history (former experience with altitude exposures) are required. Specific examinations that should be carried out are: pulsoximetry (Hb, PaCO2), spirometry, chest X-ray, RR (echocardiography). If one or more of these are abnormal, for altitude exposures above 2,500 m further tests should be carried out on air- versus O 2 -breathing: SaO2-, PaCO2-, PAP-response under supplemental O2-breathing. If still abnormal, prophylactic drug therapy is recommended: acetazolamide (250 mg b.i.d.), dexamethasone (2 mg b.i.d.), sildenafil (20 mg b.i.d.) [11, 23], nifedipine slow release (20 mg b.i.d.). In the case of ventilatory (respiratory pump, periodic breathing) insufficiency with and without lung and heart failure: polysomnography should be performed in all patients, if necesssary with and without supplemental O2-breathing and/or mechanical aids at night (CPAP, BiPAP, IPPV, added dead space) and drug therapy [9, 12, 20, 22].
Conflict of interest statement
The Matthys-Drain® was developed by the author for the drainage of air and liquid from body cavities, and is produced by firstname.lastname@example.org.
- Nussbaumer-Ochsner Y, Bloch KE: Lessons from high-altitude physiology. Breathe. 2007, 4: 123-132.Google Scholar
- Mohr LC: The hypoxia altitude simulation test: an increasingly performed test for the evaluation of patients prior to air travel. Chest. 2008, 133: 839-842. 10.1378/chest.08-0335.View ArticlePubMedGoogle Scholar
- Dillard TA, Moores LK, Bilello KL, Phillips YY: The preflight evaluation. A comparison of the hypoxia inhalation test with hypobaric exposure. Chest. 1995, 107: 352-357. 10.1378/chest.107.2.352.View ArticlePubMedGoogle Scholar
- High Altitude Medicine and Physiology. Edited by: West JB, Schoene RB, Milledge JS. 2007, London: Hodder Arnold, 4Google Scholar
- High altitude: an exploration of human adaptation. Edited by: Hornbein TF, Schoene RB. 2001, New York, Basel: Marcel Dekker IncGoogle Scholar
- Maggiorini M, Müller A, Hofstetter D, Bärtsch P, Oelz O: Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med. 1998, 69: 1186-1192.PubMedGoogle Scholar
- Bärtsch P: High altitude pulmonary edema. Respiration. 1997, 64: 435-443. 10.1159/000196720.View ArticlePubMedGoogle Scholar
- Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O: Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med. 1991, 325: 1284-1289. 10.1056/NEJM199110313251805.View ArticlePubMedGoogle Scholar
- Lovis A, de Riedmatten M, Greiner D, Delaloye A, Sartori C, Scherrer U, Heinzer R: Effects of added dead space on sleep disordered breathing at altitude (abstr). Swiss Med Wkly. 2010, 140 (Suppl 179): 3-Google Scholar
- Nussbaumer-Ochsner Y, Ursprung J, Siebenmann C, Schüpfer N, Maggiorini M, Bloch KE: Effect of dexamethasone prophylaxis on sleep and breathing disturbances in HAPE susceptible subjects after rapid ascent up 4559 m (abstr). Swiss Med Wkly. 2010, 140 (Suppl 179): 2-Google Scholar
- Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F: Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med. 2004, 141: 169-177.View ArticlePubMedGoogle Scholar
- Rexhaj E, Lovis A, Jayet PY, Rimoldi S, Allemann Y, Heinzer R, Scherrer U, Sartori C: Increasing respiratory dead space improves sleep disordered breathing and hypoxemia in patients with CMS (abstr). Swiss Med Wkly. 2010, 140 (Suppl 179): 2-Google Scholar
- Coker RK, Shiner RJ, Partridge MR: Is air travel safe for those with lung disease?. Eur Respir J. 2007, 30: 1057-1063. 10.1183/09031936.00024707.View ArticlePubMedGoogle Scholar
- British Thoracic Society Standards of Care Committee: Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax. 2002, 57: 289-304.View ArticleGoogle Scholar
- Allegra L, Cogo A, Legnani D, Diano PL, Fasano V, Negretto GG: High altitude exposure reduces bronchial responsiveness to hypo-osmolar aerosol in lowland asthmatics. Eur Respir J. 1995, 8: 1842-1846. 10.1183/09031936.95.08111842.View ArticlePubMedGoogle Scholar
- Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009, 30: 2493-2537.View ArticlePubMedGoogle Scholar
- Oades PJ, Buchdahl RM, Bush A: Prediction of hypoxaemia at high altitude in children with cystic fibrosis. BMJ. 1994, 308: 15-18. 10.1136/bmj.308.6920.15.PubMed CentralView ArticlePubMedGoogle Scholar
- Fischer R, Lang SM, Steiner U, Toepfer M, Hautmann H, Pongratz H, Huber RM: Theophylline improves acute mountain sickness. Eur Respir J. 2000, 15: 123-127. 10.1183/09031936.00.15112300.View ArticlePubMedGoogle Scholar
- Behr J, Ryu JH: Pulmonary hypertension in interstital lung disease. Eur Respir J. 2008, 31: 1357-1367. 10.1183/09031936.00171307.View ArticlePubMedGoogle Scholar
- Latshang T, Nussbaumer-Ochsner Y, Ulrich-Somaini S, Kohler M, Bloch KE: Do obstructive sleep apnea patients develop subclinical HAPE even at moderate altitude? (abstr). Swiss Med Wkly. 2010, 140 (Suppl 179): 2-Google Scholar
- Latshang T, Nussbaumer-Ochsner Y, Ulrich-Somaini S, Kohler M, Bloch KE: Combined autoCPAP and acetazolamide treatment controls breathing disturbances in patients with OSAS at altitude (abstr). Swiss Med Wkly. 2010, 140 (Suppl 179): 2-Google Scholar
- Nickol AH, Leverment J, Richards P, Seal P, Harris GA, Cleland J, Dubowitz G, Collier DJ, Milledge J, Stradling JR, Morrell MJ: Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. J Sleep Res. 2006, 15: 445-454. 10.1111/j.1365-2869.2006.00558.x.View ArticlePubMedGoogle Scholar
- Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Böhm T, Bernheim A, Kiencke S, Bloch KE, Dehnert C, Naeije R, Lehmann T, Bärtsch P, Mairbäurl H: Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006, 145: 497-506.View ArticlePubMedGoogle Scholar
- Matthys H, Volz H, Ernst N, Konietzko N: Hemodynamic and ventilatory changes in patients with obstructive airway disease exposed to a simulated altitude of 2500 m. Prog Respir Res. 1975, 9: 187-194.View ArticleGoogle Scholar